Clinical evaluation poorly predicts outcomes in lung cancer treated with immunotherapy. The aim of the study is to assess whether CT-derived texture parameters can predict overall survival (OS) and progression-free survival (PFS) in patients with advanced non-small-cell lung cancer (NSCLC) treated with first line Pembrolizumab. Twenty-one patients with NSLC were prospectively enrolled; they underwent contrast enhanced CT (CECT) at baseline and during Pembrolizumab treatment. Response to therapy was assessed both with clinical and iRECIST criteria. Two radiologists drew a volume of interest of the tumor at baseline CECT, extracting several texture parameters. ROC curves, a univariate Kaplan-Meyer analysis and Cox proportional analysis were performed to evaluate the prognostic value of texture analysis. Twelve (57%) patients showed partial response to therapy while nine (43%) had confirmed progressive disease. Among texture parameters, mean value of positive pixels (MPP) at fine and medium filters showed an AUC of 72% and 74% respectively (P < 0.001). Kaplan-Meyer analysis showed that MPP < 56.2 were significantly associated with lower OS and PFS (P < 0.0035). Cox proportional analysis showed a significant correlation between MPP4 and OS (P = 0.0038; HR = 0.89[CI 95%:0.83,0.96]). In conclusion, MPP could be used as predictive imaging biomarkers of OS and PFS in patients with NSLC with first line immune treatment.

CT based radiomic approach on first line pembrolizumab in lung cancer / Zerunian, M.; Caruso, D.; Zucchelli, A.; Polici, M.; Capalbo, C.; Filetti, M.; Mazzuca, F.; Marchetti, P.; Laghi, A.. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 11:1(2021). [10.1038/s41598-021-86113-5]

CT based radiomic approach on first line pembrolizumab in lung cancer

Zerunian M.
Co-primo
;
Caruso D.
Co-primo
;
Zucchelli A.;Polici M.;Capalbo C.;Filetti M.;Mazzuca F.;Marchetti P.
Penultimo
;
Laghi A.
Ultimo
2021

Abstract

Clinical evaluation poorly predicts outcomes in lung cancer treated with immunotherapy. The aim of the study is to assess whether CT-derived texture parameters can predict overall survival (OS) and progression-free survival (PFS) in patients with advanced non-small-cell lung cancer (NSCLC) treated with first line Pembrolizumab. Twenty-one patients with NSLC were prospectively enrolled; they underwent contrast enhanced CT (CECT) at baseline and during Pembrolizumab treatment. Response to therapy was assessed both with clinical and iRECIST criteria. Two radiologists drew a volume of interest of the tumor at baseline CECT, extracting several texture parameters. ROC curves, a univariate Kaplan-Meyer analysis and Cox proportional analysis were performed to evaluate the prognostic value of texture analysis. Twelve (57%) patients showed partial response to therapy while nine (43%) had confirmed progressive disease. Among texture parameters, mean value of positive pixels (MPP) at fine and medium filters showed an AUC of 72% and 74% respectively (P < 0.001). Kaplan-Meyer analysis showed that MPP < 56.2 were significantly associated with lower OS and PFS (P < 0.0035). Cox proportional analysis showed a significant correlation between MPP4 and OS (P = 0.0038; HR = 0.89[CI 95%:0.83,0.96]). In conclusion, MPP could be used as predictive imaging biomarkers of OS and PFS in patients with NSLC with first line immune treatment.
2021
radiomic; immunotherapy; texture parameter; overall survival (OS); pembrolizumab; non-small-cell lung cancer (NSCLC); progression-free survival (PFS)
01 Pubblicazione su rivista::01a Articolo in rivista
CT based radiomic approach on first line pembrolizumab in lung cancer / Zerunian, M.; Caruso, D.; Zucchelli, A.; Polici, M.; Capalbo, C.; Filetti, M.; Mazzuca, F.; Marchetti, P.; Laghi, A.. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 11:1(2021). [10.1038/s41598-021-86113-5]
File allegati a questo prodotto
File Dimensione Formato  
Zerunian_CT-based-radiomic_2021.pdf

accesso aperto

Note: https://www.nature.com/articles/s41598-021-86113-5
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.25 MB
Formato Adobe PDF
1.25 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1537839
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 27
social impact